Here we summarize 2020 publications where PXB-cells® were used in such application areas as lipid metabolism, toxicity, drug metabolism and hepatitis B.Hata, K. et al. Biomed. Res. 2020; 41(1):33.…
We are pleased to share information on PXB-cells NAFL-like properties first reported on PhoenixBio website.The recently published Letter to Editor (“PXB-cells, fresh primary hepatocytes from humanized mouse livers, exhibit…
An open access paper providing a detailed characterization of PXB-cells® was published in late 2020 in PLoS ONE journal. These cells are proven to be a reliable in vitro…
The assessment of safety and the toxicity profile of chemical and biological entities remains a challenge. Despite ongoing efforts to better understand the mechanisms underlying safety and toxicity, ~30%…
Oligonucleotides remain compounds of high interest in drug development, especially with recent advancements in chemistry and delivery technologies. With more compounds progressing further in preclinical development, the need for…
Environmental Health laboratory of Sumitomo Chemical Company (Japan) published a paper “Comparison of the hepatic effects of phenobarbital in chimeric mice containing either rat or human hepatocytes with humanized…
We are excited to share the Takeda team’s study results generated with the support of PhoenixBio through the Chimeric Mouse with Humanized Liver (CMHL) Consortium. The paper titled “Prediction…
Mitochondrial toxicity is one of the pathogenic mechanisms of severe drug-induced liver injury (DILI). It is desirable to identify severe DILI risks early in development, however it is extremely…
PXB-mouse® was used to assess glucuronide formation and pharmacokinetics in human hepatocytes in vivo, as published by Phenex Pharmaceuticals AG team in ACS Medicinal Chemistry Letters “Discovery of Hydroxyamidine…
Species differences in liver accumulation and metabolism of nucleotide prodrug are discussed in the April 2020 publication by Gilead team.The difficulty in projecting human dose based on preclinical data…
